Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 23 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ANTWERP PHARMACIES from Sint-Truiden, company number BE0700733344, closed financial year 2025 with a result of € 2.2 million after tax. For that financial year ANTWERP PHARMACIES recorded revenue of € 1.2 million and equity of € 4.3 million. Compared with financial year 2024, the result moved from € 234,041 to € 2.2 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 4.3 million
▲ 106% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.2 million
▲ € 2 million vs 2024
Profit after tax over the fiscal year.
€ 317,592
▲ € 254,407 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 4.3 million.
People and assets in 2025
4.4
▲ 1.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 287,384
▲ 38% vs 2024
€ 65,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 9.2 million
▼ 8% vs 2024
€ 806,603 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 33,105
▲ 259% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 48 days on average.
€ 95,056
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | € 1,195,500 | |
| Gross margin | € 719,429 | € 602,024 | € 825,375 | - | |
| Profit after taxes | € 372,321 | € 193,465 | € 234,041 | € 2,222,370 | ▲ € 2 million |
| Equity | € 1,667,556 | € 1,861,021 | € 2,095,062 | € 4,317,432 | ▲ 106% |
| Total debts | € 10,165,973 | € 11,842,344 | € 14,290,131 | € 12,591,540 | ▼ 12% |
| Cash | € 130,459 | € 131,582 | € 63,185 | € 317,592 | ▲ € 254,407 |
| Retained profit | € 1,648,956 | € 1,842,421 | € 2,076,462 | € 4,298,832 | ▲ 107% |
| Bank debt | € 7,125,026 | € 8,254,645 | € 9,968,336 | € 9,195,829 | ▼ 8% |
| Balance sheet total | € 11,833,529 | € 13,703,365 | € 16,385,193 | € 16,908,972 | ▲ 3% |
| Employees (FTE) | 2 | 2.5 | 3 | 4.4 | ▲ 1.4 |
Key figures of ANTWERP PHARMACIES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ANTWERP PHARMACIES?
What happened at ANTWERP PHARMACIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2.2 million (▲ € 2 million vs 2024). Source: NBB ↗
- Darwin NV became a director. NBB
- Jeff Roskams Consulting BV became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 372,321 profit in 2022 to € 2.2 million profit in 2025.
Paid € 324,890 in corporate taxes since 2022.
Best year ever: 2025, with € 2.2 million profit.
On average € 275,100 of value added per employee in 2024.
A new publication or filing at ANTWERP PHARMACIES? We notify you, reason included.
Follow ANTWERP PHARMACIESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Jeff Roskams Consulting comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ANTWERP PHARMACIESBehind ANTWERP PHARMACIES are Jeff Roskams Consulting BV and Darwin NV. The shares are held by Jeff Roskams Consulting (25%). It owns 100% of International Apotheek, 100% of Verlinden Apotheek, 100% of Dirk Van Herck Apotheek, 100% of Krols Apotheek, 100% of Suykerbuyk Apotheek and 100% of Europa Apotheek itself.
Directors
According to the 2025 annual accounts
Director · represented by Jeff Roskams
Also active at: INTERNATIONALE APOTHEEK, APOTHEEK VERLINDEN
since 2019
Director · represented by Joris Mees
Also active at: APOTHEEK ELZEDORP, MEES MANAGEMENT APOTHEEK, Columbus Group, MV-Management, Life Planning, DSA HOLDING, GLOBUS Q, COLUMBUS GROUP ADVICE +4 more
since 2020
Shareholders
Participations
100%
100%
100%
100%
100%
100%
100%
100%
Establishments
Establishment units
Physical locations of this company
N.B. de Borchgravestraat 4430
3800 Sint-Truiden
Groenplaats 42
2000 Antwerpen
Active since 8 August 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0700.733.344
- VAT number
- BE 0700.733.344
- Registered office
- N.B. de Borchgravestraat 4430, 3800 Sint-Truiden
- Names & denominations
- ANTWERP PHARMACIES
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 August 2018
- Peppol
- Active · Active since 12 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Handel in eigen onroerend goed
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering